Table 2.

Summary of Findings

Outcomes	Anticipated absolute effectse (95% CI)		Relative effect, OR (95% CI)	No. of participants (studies)	Certainty of the evidence (GRADE)
	Risk with control	Risk with omarigliptin
Change in HbA1c-PCG	The mean change in HbA1c in PCG was 0.12%	MD 0.58% lower (0.75 lower to 0.4 lower)	-	6,888 (10 RCTs)	⨁◯◯◯
					Very lowb,c
Proportion of subjects achieved HbA1c <7.0%-PCG	124 per 1,000	358 per 1,000 (238–499)	3.95 (2.21–7.06)	2,493 (8 RCTs)	⨁◯◯◯
					Very lowb,c
Proportion of subjects achieved HbA1c <6.5%-PCG	18 per 1,000	86 per 1,000 (47–155)	5.08 (2.64–9.89)	1,550 (5 RCTs)	⨁⨁⨁◯
					Moderateb
AEs-PCG	651 per 1,000	662 per 1,000 (605–717)	1.05 (0.82–1.36)	6,888 (10 RCTs)	⨁⨁◯◯
					Lowa,d
Serious AEs-PCG	155 per 1,000	155 per 1,000 (138–175)	1.00 (0.87–1.15)	6,888 (10 RCTs)	⨁⨁⨁⨁
					High
Hypoglycemia-PCG	154 per 1,000	179 per 1,000 (161–200)	1.20 (1.05–1.37)	6,888 (10 RCTs)	⨁⨁⨁◯
					Moderateb
Severe hypoglycemia-PCG	27 per 1,000	33 per 1,000 (25–44)	1.22 (0.91–1.65)	6,055 (8 RCTs)	⨁⨁⨁◯
					Moderated

CI, confidence interval; OR, odds ratio; HbA1c, hemoglobin A1c; PCG, passive control group; MD, mean difference; RCT, randomized controlled trial; AE, adverse event.

^aModerate heterogeneity among the studies present;

^bThe funnel plot is suggestive of an asymmetrical presence of research on each side of the central line and the presence of most of the studies outside the plot; hence, it is likely that significant publication bias is present;

^cHigh heterogeneity among the studies present;

^dThe funnel plot is suggestive of an asymmetrical presence of research on each side of the central line; hence, it is likely that significant publication bias is present;

^eThe risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).